Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers Clinical Trial

Official title:

A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of CC-93538 in Healthy Japanese and Caucasian Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04096105
• Other study ID #: CC-93538-CP-001
• Secondary ID: U1111-1238-7252
• Status: Completed
• Phase: Phase 1
• Start date: October 14, 2019
• Est. completion date: January 30, 2020

Study information

• Verified date: August 2020
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, randomized, parallel design study to evaluate the PK, safety, tolerability and immunogenicity of single SC doses of CC-93538 in healthy Japanese and Caucasian adult subjects.

A total of approximately 48 subjects, 24 Japanese and 24 Caucasians, will be enrolled. Japanese subjects will be enrolled first and randomized 1:1 to receive a single SC dose of either 180 mg or 360 mg CC-93538. Caucasian subjects will then be enrolled and matched to Japanese subjects (1:1) by weight (± 20%) and receive the same single SC dose of either 180 mg or 360 mg CC-93538.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: January 30, 2020
• Est. primary completion date: January 29, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject must be male or non-pregnant female, aged = 18 and = 55 years of age at the time of signing the ICF.

2. Subject must have a body weight of at least 40 kg; a BMI =18 and = 30 kg/m2 at screening. Japanese and Caucasian subjects will be matched by body weight (± 20%).

3. Japanese subjects must have been born in Japan and not have lived outside of Japan > 5 years, have both parents and grandparents of Japanese origin, and have not significantly modified their diets since leaving Japan.

4. Caucasian subjects must be of European or Latin American descent (ie, White).

5. Subject must be in good health, as determined by the Investigator on the basis of medical history, clinical laboratory safety test results, vital signs, 12-lead ECG, and PE at screening.

6. Female subjects not of childbearing potential must:

1. Have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before Screening, or

2. Postmenopausal (defined as 24 consecutive months without menses before Screening, with a follicle stimulating hormone [FSH] level in the postmenopausal range according to the laboratory used at Screening); FSH to be performed at the discretion of the Investigator in consultation with the Medical Monitor.

7. Females of child-bearing potential (FCBP) must agree to practice a highly effective method of contraception throughout the study and for 5 months after the last dose of investigational product (IP). Acceptable methods of birth control in this study are the following:

• Combined hormonal (containing oestrogen and progestogen) contraception, which may be oral, intravaginal, or transdermal

• Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable or implantable

• Placement of an intrauterine device or intrauterine hormone-releasing system

• Bilateral tubal occlusion

• Vasectomised partner

• Sexual abstinence

8. Male subjects must:

1. Practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to use a latex condom during sexual contact with FCBP while participating in the study until 5 months after the last dose of IP.

2. Agree to refrain from donating sperm during the study until 5 months after the last dose of IP.

Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

9. Subjects must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted, and must be able to comply with the requirements of the study, including the study visit schedule and other protocol requirements. Must be able to communicate with the Investigator and

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject has any significant medical history/condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

3. Subject has any condition that confounds the ability to interpret data from the study.

4. Subject was exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever was longer).

5. Subject has a history of infection within 30 days of dosing on Day 1.

6. Subject has a history of drug or alcohol abuse (as defined by the investigator), or addiction within 6 months prior to Screening.

7. Subject has used any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, electronic cigarettes, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 3 months prior to Day 1 and during the study.

8. Subject has a positive urine drug test including cotinine, or positive alcohol urine or breath test at Screening or on Day -1.

9. Subject has donated greater than 400 mL of blood within 60 days prior to Day 1.

10. Subject has a positive serum test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).

11. Subject has a history of clinically significant allergic reaction to any drug, biologic, food, or vaccine.

12. Subject has a history of major immunologic reaction (such as anaphylactic reaction, anaphylactoid reaction, or serum sickness) to any IgG-containing agent.

13. Subject fails or is unwilling to abstain from strenuous physical activities for at least 24 hours prior to dosing (Day 1) and throughout the study

14. Subject has tattoos (> 25% of their body) or other skin markings (eg, scars) that, in the opinion of the investigator, would prevent visualization of dermatologic changes due to study treatment

15. Subject has been diagnosed with or is being treated for a parasitic/helminthic infection or subject has systemic or diarrheal illness following travel or residence in endemic areas of parasitic/helminthic infections, history of clinical schistosomiasis, and history of travel to endemic areas within preceding 6 months.

16. Subject has a history of tuberculosis, listeriosis, or untreated parasitic infections.

17. Subject has a history of hereditary fructose intolerance.

18. Subject is, for any reason, deemed by the Investigator to be inappropriate for this study.

19. Subject has received any drug by injection within 30 days of Day 1.

20. Subject has poor peripheral venous access.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• CC-93538
a single dose CC-93538 SC

Locations

Country	Name	City	State
United States	Anaheim Clinical Trials	Anaheim	California

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics - AUC0-last	Area under the concentration-time curve calculated from time zero to the last measured concentration	from pre-dose to up to Day 70
Primary	Pharmacokinetics - AUC0-8	Area under the concentration-time curve calculated from time zero to infinity	from pre-dose to up to Day 70
Primary	Pharmacokinetics - Cmax	Maximum observed concentration of drug	from pre-dose to up to Day 70
Primary	Pharmacokinetics - tmax	Time to Cmax	from pre-dose to up to Day 70
Primary	Pharmacokinetics - t½	Terminal elimination half-life	from pre-dose to up to Day 70
Primary	Pharmacokinetics - CL/F	Apparent clearance of drug from serum after extravascular administration	from pre-dose to up to Day 70
Primary	Pharmacokinetics - Vz/F	Apparent volume of distribution during the terminal phase	from pre-dose to up to Day 70
Secondary	Adverse Events (AEs)	Number participants with adverse event	From the time the informed consent form (ICF) is signed and until 70 days after the last dose of CC-93538
Secondary	Immunogenicity profile for CC-93538	Positive or negative for the presence of antidrug antibodies against CC-93538 in blood	from pre-dose to up to Day 70